We are live on
!
Find out more
EAM
Exome Asset Management Portfolio holdings
AUM
$193M
1-Year Est. Return
208.51%
This Fund
S&P 500
This Quarter
Est. Return
+82%
1 Year Est. Return
+208.51%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$209M
AUM Growth
+$44M
(+27%)
Cap. Flow
-$21.4M
Cap. Flow
% of AUM
-10.24%
Top 10 Holdings %
Top 10 Hldgs %
42.68%
Holding
94
New
26
Increased
5
Reduced
16
Closed
34
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Elevance Health
ELV
|
+$5.81M |
| 2 |
Agios Pharmaceuticals
AGIO
|
+$4.8M |
| 3 |
Enliven Therapeutics
ELVN
|
+$4.43M |
| 4 |
Wave Life Sciences
WVE
|
+$4.28M |
| 5 |
Jazz Pharmaceuticals
JAZZ
|
+$4.06M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Praxis Precision Medicines
PRAX
|
+$8.17M |
| 2 |
NBP
NovaBridge Biosciences American Depositary Shares
NBP
|
+$4.16M |
| 3 |
ETNB
89bio
ETNB
|
+$4.02M |
| 4 |
Cogent Biosciences
COGT
|
+$3.88M |
| 5 |
Apogee Therapeutics
APGE
|
+$3.75M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Praxis Precision Medicines
PRAX
$8.99B
| $17.1M | 8.19% |
58,122
-43,874
| -43% | -$8.17M |
|
|
2
Cogent Biosciences
COGT
$6.88B
| $10.9M | 5.19% |
305,568
-137,979
| -31% | -$3.88M |
|
3
Guardant Health
GH
$19.9B
| $10M | 4.79% |
98,182
| – | – |
|
4
Ionis Pharmaceuticals
IONS
$9.23B
| $9.22M | 4.41% |
116,515
-14,501
| -11% | -$1.09M |
|
5
Eli Lilly
LLY
$1.06T
| $8.44M | 4.03% |
7,852
| – | – |
|
6
Cytokinetics
CYTK
$11.1B
| $7.93M | 3.79% |
124,749
-17,668
| -12% | -$1.1M |
|
|
7
Wave Life Sciences
WVE
$1.11B
| $7.17M | 3.43% |
+421,488
| New | +$4.28M |
|
8
Vera Therapeutics
VERA
$2.61B
| $6.3M | 3.01% |
124,391
-31,681
| -20% | -$1.13M |
|
9
BridgeBio Pharma
BBIO
$16.2B
| $6.17M | 2.95% |
80,723
-52,364
| -39% | -$3.44M |
|
|
10
Elevance Health
ELV
$82.3B
| $6.03M | 2.88% |
+17,191
| New | +$5.81M |
|
11
AstraZeneca
AZN
$261B
| $5.26M | 2.52% |
14,181
| – | – |
|
|
12
Jazz Pharmaceuticals
JAZZ
$16B
| $4.5M | 2.15% |
+26,494
| New | +$4.06M |
|
13
Natera
NTRA
$37.9B
| $4.27M | 2.04% |
18,650
| – | – |
|
14
Immunovant
IMVT
$8.08B
| $4.03M | 1.93% |
158,622
| – | – |
|
15
Universal Health Services
UHS
$9.16B
| $3.84M | 1.84% |
17,628
+9,673
| +122% | +$2.14M |
|
16
United Therapeutics
UTHR
$26.4B
| $3.74M | 1.79% |
7,685
+1,040
| +16% | +$484K |
|
|
17
Agios Pharmaceuticals
AGIO
$2.16B
| $3.73M | 1.78% |
+136,942
| New | +$4.8M |
|
18
Disc Medicine
IRON
$2.9B
| $3.71M | 1.77% |
46,743
-14,613
| -24% | -$1.23M |
|
19
Intuitive Surgical
ISRG
$119B
| $3.6M | 1.72% |
6,358
| – | – |
|
20
Glaukos
GKOS
$8.94B
| $3.55M | 1.7% |
31,471
+4,328
| +16% | +$414K |
|
|
21
Enliven Therapeutics
ELVN
$3.77B
| $3.42M | 1.64% |
+222,308
| New | +$4.43M |
|
22
Celcuity
CELC
$4.31B
| $3.42M | 1.64% |
+34,289
| New | +$2.82M |
|
|
APLS
23
DELISTED
Apellis Pharmaceuticals
APLS
| $3.41M | 1.63% |
+135,849
| New | +$3.19M |
|
24
Travere Therapeutics
TVTX
$5.27B
| $3.4M | 1.63% |
89,052
-67,865
| -43% | -$2.21M |
|
25
DexCom
DXCM
$27.2B
| $3.33M | 1.59% |
+50,147
| New | +$3.24M |
|
Similar funds
WWC
JHA
TDWM
MUAMU
DF
BW
SCM
CWRP
Exome Asset Management's Q4 2025 Portfolio in Review
As of Q4 2025, Exome Asset Management held 94 positions worth $209M, up 27% from $165M the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Exome Asset Management withdrew a net $21.4M in Q4 2025, closing 34 positions and reducing 16 holdings. Its most notable exit was 89bio, an estimated $4.02M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 90% a quarter earlier.
Against the trend, Exome Asset Management opened a new position in Elevance Health worth $6.03M.
- Exome Asset Management's largest Q4 2025 buy was Elevance Health: 17,191 shares worth $6.03M.
- Exome Asset Management added most to Universal Health Services in Q4 2025, an estimated $2.14M increase.
- Exome Asset Management's biggest Q4 2025 reduction was Praxis Precision Medicines, cutting an estimated $8.17M.
- Exome Asset Management fully exited 89bio in Q4 2025, selling an estimated $4.02M.
- Exome Asset Management's ten largest holdings make up 43% of its $209M portfolio in Q4 2025.
- Exome Asset Management opened 26 new positions and closed 34 in Q4 2025.
- Exome Asset Management's portfolio value rose 27% quarter-over-quarter to $209M.
Based on Exome Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.